213 related articles for article (PubMed ID: 31981082)
21. Key elements in adverse drug interaction safety signals: an assessment of individual case safety reports.
Strandell J; Norén GN; Hägg S
Drug Saf; 2013 Jan; 36(1):63-70. PubMed ID: 23315297
[TBL] [Abstract][Full Text] [Related]
22. International Conference on Harmonisation; Electronic Transmission of Postmarket Individual Case Safety Reports for Drugs and Biologics, Excluding Vaccines; Availability of Food and Drug Administration Regional Implementation Specifications for ICH E2B(R3) Reporting to the Food and Drug Administration Adverse Event Reporting System. Notice of Availability.
Food and Drug Administration, HHS
Fed Regist; 2016 Jun; 81(121):40890-1. PubMed ID: 27373012
[TBL] [Abstract][Full Text] [Related]
23. Implementation and comparison of two text mining methods with a standard pharmacovigilance method for signal detection of medication errors.
Eskildsen NK; Eriksson R; Christensen SB; Aghassipour TS; Bygsø MJ; Brunak S; Hansen SL
BMC Med Inform Decis Mak; 2020 May; 20(1):94. PubMed ID: 32448248
[TBL] [Abstract][Full Text] [Related]
24. Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis.
Araujo AGS; Lucchetta RC; Tonin FS; Pontarolo R; Borba HHL; Wiens A
Expert Opin Drug Saf; 2021 Jun; 20(6):735-740. PubMed ID: 33641547
[No Abstract] [Full Text] [Related]
25. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
Castillon G; Salvo F; Moride Y
Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
[TBL] [Abstract][Full Text] [Related]
26. Assessment of factors associated with completeness of spontaneous adverse event reporting in the United States: A comparison between consumer reports and healthcare professional reports.
Toki T; Ono S
J Clin Pharm Ther; 2020 Jun; 45(3):462-469. PubMed ID: 31765498
[TBL] [Abstract][Full Text] [Related]
27. Drug-Related Deaths in China: An Analysis of a Spontaneous Reporting System.
Li H; Deng J; Yu P; Ren X
Front Pharmacol; 2022; 13():771953. PubMed ID: 35281929
[No Abstract] [Full Text] [Related]
28. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
Masuka JT; Khoza S
BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
[TBL] [Abstract][Full Text] [Related]
29. Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.
Cherkas Y; Ide J; van Stekelenborg J
Drug Saf; 2022 May; 45(5):571-582. PubMed ID: 35579819
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.
Pierce CE; Bouri K; Pamer C; Proestel S; Rodriguez HW; Van Le H; Freifeld CC; Brownstein JS; Walderhaug M; Edwards IR; Dasgupta N
Drug Saf; 2017 Apr; 40(4):317-331. PubMed ID: 28044249
[TBL] [Abstract][Full Text] [Related]
31. Individual case safety reports--how to determine the onset date of an adverse reaction: a survey.
Klepper MJ; Edwards B
Drug Saf; 2011 Apr; 34(4):299-305. PubMed ID: 21417502
[TBL] [Abstract][Full Text] [Related]
32. Feature engineering and machine learning for causality assessment in pharmacovigilance: Lessons learned from application to the FDA Adverse Event Reporting System.
Kreimeyer K; Dang O; Spiker J; Muñoz MA; Rosner G; Ball R; Botsis T
Comput Biol Med; 2021 Aug; 135():104517. PubMed ID: 34130003
[TBL] [Abstract][Full Text] [Related]
33. Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study.
Avong YK; Jatau B; Gurumnaan R; Danat N; Okuma J; Usman I; Mordi D; Ukpabi B; Kayode GA; Dutt S; El-Tayeb O; Afolabi B; Ambrose I; Agbaji O; Osakwe A; Ibrahim A; Ogar C; Nosiri H; Avong EB; Adekanmbi V; Uthman O; Abimiku A; Oni YO; Mensah CO; Dakum P; Mberu KE; Ogundahunsi OAT
PLoS One; 2018; 13(8):e0200810. PubMed ID: 30133453
[TBL] [Abstract][Full Text] [Related]
34. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.
Brajovic S; Piazza-Hepp T; Swartz L; Dal Pan G
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):565-70; discussion 571-2. PubMed ID: 22359404
[TBL] [Abstract][Full Text] [Related]
35. Increasing Patient Engagement in Pharmacovigilance Through Online Community Outreach and Mobile Reporting Applications: An Analysis of Adverse Event Reporting for the Essure Device in the US.
Bahk CY; Goshgarian M; Donahue K; Freifeld CC; Menone CM; Pierce CE; Rodriguez H; Brownstein JS; Furberg R; Dasgupta N
Pharmaceut Med; 2015; 29(6):331-340. PubMed ID: 26635479
[TBL] [Abstract][Full Text] [Related]
36. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
37. Individual Case Safety Reports Analysis for Patients with Diabetes Mellitus on Insulin in Africa and the Middle East.
Mlotshwa CRN; Burger JR; Vorster M; Rakumakoe DM; Cockeran M
Curr Drug Saf; 2022; 17(3):225-234. PubMed ID: 34749625
[TBL] [Abstract][Full Text] [Related]
38. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
[TBL] [Abstract][Full Text] [Related]
39. Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase.
Samukange WT; Lu TA; Souverein PC; Gardarsdottir H; Mantel-Teeuwisse AK
Transfusion; 2023 May; 63(5):982-992. PubMed ID: 36994873
[TBL] [Abstract][Full Text] [Related]
40. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
